AZOR Drug Patent Profile
✉ Email this page to a colleague
When do Azor patents expire, and what generic alternatives are available?
Azor is a drug marketed by Cosette and is included in one NDA.
The generic ingredient in AZOR is amlodipine besylate; olmesartan medoxomil. There are fifty drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the amlodipine besylate; olmesartan medoxomil profile page.
Summary for AZOR
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 3 |
| Raw Ingredient (Bulk) Api Vendors: | 42 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for AZOR |
| What excipients (inactive ingredients) are in AZOR? | AZOR excipients list |
| DailyMed Link: | AZOR at DailyMed |
Pharmacology for AZOR
Anatomical Therapeutic Chemical (ATC) Classes for AZOR
Paragraph IV (Patent) Challenges for AZOR
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| AZOR | Tablets | amlodipine besylate; olmesartan medoxomil | 10 mg/20 mg and 5 mg/40 mg | 022100 | 1 | 2008-03-31 |
| AZOR | Tablets | amlodipine besylate; olmesartan medoxomil | 5 mg/20 mg and 10 mg/40 mg | 022100 | 1 | 2008-02-11 |
US Patents and Regulatory Information for AZOR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cosette | AZOR | amlodipine besylate; olmesartan medoxomil | TABLET;ORAL | 022100-001 | Sep 26, 2007 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Cosette | AZOR | amlodipine besylate; olmesartan medoxomil | TABLET;ORAL | 022100-004 | Sep 26, 2007 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Cosette | AZOR | amlodipine besylate; olmesartan medoxomil | TABLET;ORAL | 022100-002 | Sep 26, 2007 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Cosette | AZOR | amlodipine besylate; olmesartan medoxomil | TABLET;ORAL | 022100-003 | Sep 26, 2007 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for AZOR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Cosette | AZOR | amlodipine besylate; olmesartan medoxomil | TABLET;ORAL | 022100-003 | Sep 26, 2007 | ⤷ Try a Trial | ⤷ Try a Trial |
| Cosette | AZOR | amlodipine besylate; olmesartan medoxomil | TABLET;ORAL | 022100-004 | Sep 26, 2007 | ⤷ Try a Trial | ⤷ Try a Trial |
| Cosette | AZOR | amlodipine besylate; olmesartan medoxomil | TABLET;ORAL | 022100-001 | Sep 26, 2007 | ⤷ Try a Trial | ⤷ Try a Trial |
| Cosette | AZOR | amlodipine besylate; olmesartan medoxomil | TABLET;ORAL | 022100-002 | Sep 26, 2007 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for AZOR
See the table below for patents covering AZOR around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Germany | 69231798 | ⤷ Try a Trial | |
| Norway | 2009019 | ⤷ Try a Trial | |
| Ireland | 970752 | ⤷ Try a Trial | |
| Russian Federation | 2086541 | ПРОИЗВОДНЫЕ ИМИДАЗОЛА ИЛИ ИХ ФАРМАЦЕВТИЧЕСКИ ПРИЕМЛЕМЫЕ СЛОЖНЫЕ ЭФИРЫ И СПОСОБ ИХ ПОЛУЧЕНИЯ (IMIDAZOLE DERIVATIVES OR THEIR PHARMACEUTICALLY ACCEPTABLE ESTERS AND A METHOD OF THEIR SYNTHESIS) | ⤷ Try a Trial |
| Taiwan | 228521 | ⤷ Try a Trial | |
| Hong Kong | 1011361 | ⤷ Try a Trial | |
| Czech Republic | 289244 | 1-Bifenylmethylimidazolové deriváty, způsob výroby a farmaceutické prostředky s jejich obsahem (1-Biphenylmethylimidazole derivatives, process of their preparation and pharmaceutical preparations in which they are comprised) | ⤷ Try a Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for AZOR
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1003503 | 05C0048 | France | ⤷ Try a Trial | PRODUCT NAME: AMLODIPINE OU UN DE SES SELS D?ADDITION D?ACIDES PHARMACAUTIQUEMENT ACCEPTABLES/ ATORVASTATINE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE IN FRANCE: NL 29929 DU 20050707; REGISTRATION NO/DATE AT EEC: NL 29929 DU 20050707 |
| 0503785 | CA 2009 00015 | Denmark | ⤷ Try a Trial | PRODUCT NAME: EN KOMBINATION AF OLMESARTANMEDOXOMIL, EVT. I FORM AF ET FARMACEUTISK ACCEPTABELT SALT OG AMLODIPIN-BESILAT; NAT. REG. NO/DATE: MT 42061, 42062, 42063 20081120; FIRST REG. NO/DATE: NL RVG 100984 20080819 |
| 0503785 | C300486 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: COMBINATIE VAN OLMESARTANMEDOXOMIL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, AMLODIPINEBESYLAAT AND HYDROCHLOORTHIAZIDE; NATL REGISTRATION NO/DATE: RVG 106667, RVG 106671-74, RVG 106682-86 20101221; FIRST REGISTRATION: DE 79810.00.00-79814.00.00 20101216 |
| 0503785 | 91330 | Luxembourg | ⤷ Try a Trial | CERTIFICATE TITLE: UNE COMBINAISON D'OLMESARTAN MEDOXOMIL, OPTIONNELLEMENT SOUS LA FORME D'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE ET D'HYDROCHLOROTHIAZIDE (OLMETEC PLUS) |
| 0503785 | C00503785/04 | Switzerland | ⤷ Try a Trial | FORMER REPRESENTATIVE: BOHEST AG, CH |
| 0503785 | C00503785/01 | Switzerland | ⤷ Try a Trial | FORMER OWNER: SANKYO COMPANY LIMITED, JP |
| 0443983 | C00443983/03 | Switzerland | ⤷ Try a Trial | PRODUCT NAME: VALSARTAN + AMLODIPINE + HYDROCHLOROTHIAZIDE; REGISTRATION NUMBER/DATE: SWISSMEDIC 59407 16.09.2009 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
